5-Bromo-3-(trifluoromethyl)picolinaldehyde, 95.0%, 5g

4-Bromo-benzimidic acid ethyl ester; hydrochloride, 90.0%, 1g

2-{3-oxo-2h,3h-[1,2,4]triazolo[4,3-a]pyridin-2-yl}acetonitrile, 95%, 250mg

(S)-2-(2-Aminoacetamido)-3-(4-hydroxyphenyl)propanoic acid hydrate, 95.0%, 1g

2-Fluoro-4-(pentafluorosulfur)benzoyl chloride, 1g

(2E)-1-(2-methylphenyl)-3-(3-methylphenyl)prop-2-en-1-one, 95.0%, 2g

4-Methyloxazole, 95.0%, 25g

3-Methyl-1H-pyrazole-4-carbonitrile, 95.0%, 5g

iScope IS.1153-PLPHi Triocular with Plan phase IOS objectives and Rackless cross table (infinity)

2-(3-methyl-1H-pyrazol-5-yl)acetonitrile, 95.0%, 250mg

3,5-Dichloro-1,2,4-thiadiazole, 97.0%, 2.5g

7-CARBOXY-1H-INDAZOLE, 95%, 100g

4-((Tert-butoxycarbonyl)amino)-1-fluorocyclohexane-1-carboxylic acid, 98%, 250mg